Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Environ Pollut ; 341: 122945, 2024 Jan 15.
Article in English | MEDLINE | ID: mdl-37984472

ABSTRACT

Polluted resources of potable water are daily used for different purposes in Lebanon. The optical microscopy is the traditional method used for the detection of Entamoeba spp. in water despite its weak sensitivity. We aimed to characterize domestic water at Nabatieh district, South Lebanon, and to develop a simple method for Entamoeba spp. detection. A total of 70 water samples were collected from houses and schools and analyzed for physical (pH, total dissolved solids and temperature), chemical (nitrate, phosphate and sulfate) and bacterial (total and fecal coliforms) parameters. The contamination by Entamoeba spp. was examined using microscopy, then a spectrophotometric wavelength scan was recorded for 50 samples in order to determine the common peak between positive samples. High phosphate levels were detected in all the samples, with important bacterial and parasitological contaminations. The spectrophotometric analyses showed a peak repetition at the wavelength of 696 nm in the spectrum of the majority of positive samples. The number of cysts was significantly correlated to optical densities at 696 nm (R = 0.9087; p-value<0.0001). The regression analysis showed that the OD696 could statistically predict the concentration (F (1,48) = 267.02, p-value <0.001). In conclusion, potable water parameters at Nabatieh district did not meet the national and international guidelines of safe drinking water, and the detection of Entamoeba spp. cysts in potable water can be performed using a rapid spectrophotometric analysis, by the determination of the optical density at 696 nm and the application of a specific equation.


Subject(s)
Cysts , Drinking Water , Entamoeba , Humans , Water Quality , Lebanon , Bacteria , Schools , Phosphates
2.
Mol Biol Rep ; 48(1): 875-886, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33389539

ABSTRACT

Cardiovascular diseases (CVD) have overtaken infectious diseases and are currently the world's top killer. A quite strong linkage between this type of ailments and elevated plasma levels of triglycerides (TG) has been always noticed. Notably, this risk factor is mired in deep confusion, since its role in atherosclerosis is uncertain. One of the explanations that aim to decipher this persistent enigma was provided by apolipoprotein C-III (apoC-III), a small protein historically recognized as an important regulator of TG metabolism. Preeminently, hundreds of studies have been carried out in order to explore the APOC3 genetic background, as well as to establish a correlation between its variants and dyslipidemia-related disorders, pointing to an earnest predictive power for future outcomes. Among several polymorphisms reported within the APOC3, the SstI site in its 3'-untranslated region (3'-UTR) was the most consistently and robustly associated with an increased CVD risk. As more genetic data supporting its importance in cardiovascular events aggregate, it was declared, correspondingly, that apoC-III exerts various atherogenic effects, either by intervening in the function and catabolism of many lipoproteins, or by inducing endothelial inflammation and smooth muscle cells (SMC) proliferation. This review was designed to shed the light on the structural and functional aspects of the APOC3 gene, the existing association between its SstI polymorphism and CVD, and the specific molecular mechanisms that underlie apoC-III pathological implications. In addition, the translation of all these gathered knowledges into preventive and therapeutic benefits will be detailed too.


Subject(s)
Apolipoprotein C-III/genetics , Atherosclerosis/genetics , Hyperlipoproteinemia Type I/genetics , Hypertriglyceridemia/genetics , Plaque, Atherosclerotic/genetics , Polymorphism, Genetic , 3' Untranslated Regions , Apolipoprotein C-III/antagonists & inhibitors , Apolipoprotein C-III/blood , Atherosclerosis/blood , Atherosclerosis/drug therapy , Atherosclerosis/pathology , Cardiovascular Agents/therapeutic use , Clinical Trials as Topic , Gene Expression , Humans , Hyperlipoproteinemia Type I/blood , Hyperlipoproteinemia Type I/drug therapy , Hyperlipoproteinemia Type I/pathology , Hypertriglyceridemia/blood , Hypertriglyceridemia/drug therapy , Hypertriglyceridemia/pathology , Oligonucleotides/therapeutic use , Plaque, Atherosclerotic/blood , Plaque, Atherosclerotic/drug therapy , Plaque, Atherosclerotic/pathology , Risk Factors , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...